Treatment of Acute Motor Axonal Neuropathy

Introduction to Treatment Options

The American Academy of Neurology recommends that both IVIg (0.4 g/kg/day for 5 days) and plasma exchange (200-250 ml/kg over 5 sessions) are considered equally effective first-line treatments for the AMAN variant of Guillain-Barré Syndrome, though IVIg is generally preferred due to easier administration, wider availability, and higher completion rates 1, 2

Current guidelines do not differentiate treatment recommendations between AMAN and AIDP subtypes, and both IVIg and plasma exchange remain standard first-line options for all GBS variants 1, 2
IVIg is easier to administer, more widely available, and has significantly higher completion rates compared to plasma exchange 1, 4

Administer IVIg at 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg) 1, 2, 3
Treatment should be initiated within 2 weeks of symptom onset for patients unable to walk unaided 3

Admission to a monitored unit with rapid ICU transfer capability is required, as approximately 25% of GBS patients develop respiratory failure 3, 5
Frequent respiratory function monitoring using the "20/30/40 rule" is necessary: patient at risk if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 2, 3
Calculation of EGRIS (Erasmus GBS Respiratory Insufficiency Score) to predict probability of requiring mechanical ventilation within 1 week 1, 3

Never use corticosteroids alone, as they are ineffective and may worsen outcomes 1, 3
Avoid medications that worsen neuromuscular function: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 2, 3
Do not routinely give a second course of IVIg to patients with poor prognosis, as this increases serious adverse events without proven benefit (except in treatment-related fluctuations occurring within 2 months) 3

Approximately 40% of patients do not improve in the first 4 weeks following treatment, which does not necessarily indicate treatment failure 2, 3
About 80% of patients regain walking ability at 6 months, though mortality remains 3-10%, primarily from cardiovascular and respiratory complications 2, 5
Treatment-related fluctuations occur in 6-10% of patients within 2 months; repeating the full IVIg course is appropriate for these cases 2, 3